ArticleClinical and translational radiation oncology2026
Preoperative hypofractionated radiotherapy in soft tissue sarcomas: institutional experience and clinical implications.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Radiotherapy for Soft Tissue Sarcomas in 2025: A Review.Current oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Conventional preoperative radiotherapy (RT) with 50 Gy in 25 fractions improves local control in soft tissue sarcomas (STS) but entails prolonged treatment and high rates of wound complications. Hypofractionated regimens may offer a shorter, more patient-convenient alternative while maintaining comparable outcomes, although they are not yet standard. Materials and methods: We conducted an observational study of a prospective cohort of 24 patients with localized STS of the extremities or superficial trunk treated with preoperative hypofractionated RT between December 2021 and January 2025. Two regimens were used: moderately hypofractionated RT (MHFRT, 42.75 Gy/15 fx) and ultra-hypofractionated RT (UHFRT, 30 Gy/5 fx). Outcomes included acute toxicity, wound complications, pathological response, local control, and postoperative limb function using the Musculoskeletal Tumor Society (MSTS) and Toronto Extremity Salvage Score (TESS) scales. Results: The median age was 68 years, and median tumor size 11.6 cm. All patients completed RT without interruption. A favorable pathological response (≥90% necrosis and/or ≤ 10% viable tumor) was achieved in 66.7%. Grade 1-2 dermatitis occurred in 66.7%, with no grade ≥ 3 toxicity. Major wound complications developed in 29.2%. Median MSTS and TESS scores were 26/30 (86.7%) and 88%, respectively. At 18 months median follow-up, 1- and 2-year local control rates were 100%. Conclusions: Preoperative hypofractionated RT demonstrated excellent tolerance, high pathological response, and outstanding local control with acceptable wound-complication rates. Functional outcomes were favorable, supporting hypofractionated RT as a safe, efficient, and function-preserving alternative for localized STS in experienced centers. These findings provide real-world evidence supporting shorter preoperative RT schedules as a feasible and function-preserving approach in multidisciplinary sarcoma care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.